Barclays’s Liminatus Pharma LIMN Stock Holding History

Barclays’s Portfolio LIMN Stock Details LIMN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-184	Closed	-$2.05K	–	5788
2025 Q2	$2.05K	Buy	+184	New	+$2.07K	﹤0.01%	5037

Other funds holding LIMN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Barclays's LIMN Position: Q3 2025 in Review

Barclays sold out of Liminatus Pharma (LIMN) in Q3 2025, closing a stake of 184 shares — an estimated $2.05K sold.

Barclays first reported a position in LIMN in Q2 2025 and held it in 1 quarter. The position peaked at $2.05K in Q2 2025. 10 funds tracked by Wall St. Rank hold LIMN as of Q3 2025.

Barclays reported no remaining Liminatus Pharma position as of Q3 2025 after selling out during the quarter.
Barclays sold 184 Liminatus Pharma shares in Q3 2025, an estimated $2.05K.
Barclays first reported a position in Liminatus Pharma in Q2 2025 and held it in 1 quarter.
Barclays's Liminatus Pharma position peaked at $2.05K in Q2 2025.
10 funds tracked by Wall St. Rank held Liminatus Pharma as of Q3 2025.

Based on Barclays's 13F filing for Q3 2025, filed 12 Nov 2025.